Shots:
- The company presents the ongoing program of SARS-CoV-2 mutation surveillance for STI-2020 currently in pre/ clinical development for COVID-19
- The data provides evidence of maintained binding potency in in vitro assays including the Spike amino acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage, identified in the UK
- Additional neutralizing Abs were identified that bind strongly to the B.1.1.7 & B.1.351 spike proteins and are under analyses for neutralization activities both in vitro and in vivo. Sorrento to unveils early in vitro results of diminished STI-2020 binding potency in assays including Spike proteins derived from viruses of the B.1.351 lineage, identified in SA
Click here to read full press release/ article | Ref: Sorrento | Image: Analyze Markets
The post Sorrento Presents Preliminary Results of STI-2020 Against COVID-19 first appeared on PharmaShots.
